Do Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From...

Area of Science:

• Dermatology
• Clinical Research
• Patient-Reported Outcomes

Background:

• Sparse research exists on the correlation between clinician-reported validated Investigator Global Assessment for AD (vIGA-AD) and patient-reported disease burden.
• Understanding this relationship is crucial for comprehensive atopic dermatitis (AD) management.

Purpose of the Study:

• To evaluate the association between vIGA-AD and patient-reported disease severity and quality of life (QoL) in a real-world AD cohort.
• To determine if clinician assessments align with patient experiences of AD.

Main Methods:

• Cross-sectional analysis of the TARGET-DERM AD study (n=1,888) including children, adolescents, and adults.
• Clinical AD severity measured by vIGA-AD; patient-reported outcomes assessed using Patient Oriented Eczema Measure (POEM) and (Children’s) Dermatology Life Quality Index (C/DLQI).
• Statistical analyses included descriptive statistics, unadjusted and adjusted ordinal logistic regression, and linear regression models.

Main Results:

• Greater vIGA-AD severity correlated with higher POEM scores (adults r=0.496, pediatrics r=0.45) and greater C/DLQI/DLQI scores (adults r=0.458, pediatrics r=0.334).
• Adjusted models confirmed significant associations: moderate-to-severe AD patients were 8.19x (adults) and 5.78x (pediatrics) more likely to report severe POEM outcomes.
• Moderate-to-severe AD patients were 6.69x (adults) and 3.74x (pediatrics) more likely to report worse QoL (DLQI/C/DLQI).

Conclusions:

• Clinician-assessed AD severity (vIGA-AD) is positively correlated with patient-reported disease severity and reduced quality of life.
• Findings support the alignment of clinical and patient perspectives in evaluating AD burden.
• This correlation underscores the utility of vIGA-AD in reflecting the overall impact of AD on patients.